Evidence map›Paper›PMID 18829740›Full record

ArticleAmerican journal of physiology. Renal physiology2008

Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1.

Neal I Alcalay, Madhulika Sharma, Dianne Vassmer, Brandon Chapman, Binu Paul, Jing Zhou, Jennifer G Brantley, Darren P Wallace, Robin L Maser, Gregory B Vanden Heuvel

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Renal physiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Specialized roles for cysteine cathepsins in health and disease.The Journal of clinical investigation · 2010
    Review
  18. Kidney: polycystic kidney disease.Wiley interdisciplinary reviews. Developmental biology
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Neal I AlcalayDepartment of Anatomy and Cell Biology, Univ. of Kansas Medical Center, Kansas City, KS 66160, USA.
Madhulika Sharma
Dianne Vassmer
Brandon Chapman
Binu Paul
Jing Zhou
Jennifer G Brantley
Darren P Wallace
Robin L Maser
Gregory B Vanden Heuvel
University of Kansas Medical Center · US

Funding

ROLE OF OXIDANT STRESS IN PROGRESSION OF PKDP50DK057301 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI CALVET, JAMES P · 1999 to 2009
$11.3M
Cux-1 and Cell Cycle Regulation in Kidney DevelopmentR01DK058377 · NIDDK · UNIVERSITY OF KANSAS MEDICAL CENTER · PI VANDEN HEUVEL, GREGORY B · 2001 to 2009
$2.4M
NIDDK NIH HHS P50 DK057301NIDDK NIH HHS P50-DK-57301NIDDK NIH HHS R01-DK-58377
6 · The paper itself

Abstract

Polycystic kidney diseases (PKD) are inherited as autosomal dominant (ADPKD) or autosomal recessive (ARPKD) traits and are characterized by progressive enlargement of renal cysts. Aberrant cell proliferation is a key feature in the progression of PKD. Cux1 is a homeobox gene that is related to Drosophila cut and is the murine homolog of human CDP (CCAAT Displacement Protein). Cux1 represses the cyclin kinase inhibitors p21 and p27, and transgenic mice ectopically expressing Cux1 develop renal hyperplasia. However, Cux1 transgenic mice do not develop PKD. Here, we show that a 246 amino acid deletion in Cux1 accelerates PKD progression in cpk mice. Cystic kidneys isolated from 10-day-old cpk/Cux1 double mutant mice were significantly larger than kidneys from 10-day-old cpk mice. Moreover, renal function was significantly reduced in the Cux1 mutant cpk mice, compared with cpk mice. The mutant Cux1 protein was ectopically expressed in cyst-lining cells, where expression corresponded to increased cell proliferation and apoptosis, and a decrease in expression of the cyclin kinase inhibitors p27 and p21. While the mutant Cux1 protein altered PKD progression, kidneys from mice carrying the mutant Cux1 protein alone were phenotypically normal, suggesting the Cux1 mutation modifies PKD progression in cpk mice. During cell cycle progression, Cux1 is proteolytically processed by a nuclear isoform of the cysteine protease cathepsin-L. Analysis of the deleted sequences reveals that a cathepsin-L processing site in Cux1 is deleted. Moreover, nuclear cathepsin-L is significantly reduced in both human ADPKD cells and in Pkd1 null kidneys, corresponding to increased levels of Cux1 protein in the cystic cells and kidneys. These results suggest a mechanism in which reduced Cux1 processing by cathepsin-L results in the accumulation of Cux1, downregulation of p21/p27, and increased cell proliferation in PKD.

Indexed as

AnimalsCathepsin LCathepsinsCrosses, GeneticCysteine EndopeptidasesDisease ProgressionHomeodomain ProteinsHumansMiceMice, KnockoutMutationNuclear ProteinsOrgan SizePolycystic Kidney, Autosomal DominantPolycystic Kidney DiseasesRepressor ProteinsCathepsin LCathepsinsCTSL protein, humanCtsl protein, mouseCux1 protein, mouseCysteine EndopeptidasesHomeodomain ProteinsNuclear ProteinsRepressor Proteins

Identifiers

PMID18829740
PMCPMC2604819
OpenAlexW2161408733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.